Resource Center
Explore Resource Types
Focused Solutions
![biologics](https://resources.revvity.com/images/biologics_512x288.jpg)
Biologics
Make advancements with precision biologics tools, designed to enhance your therapeutic approaches encompassing monoclonal antibodies, recombinant proteins, vaccines, and targeted next-generation cell and gene therapies.
![cell-and-gene-therapy-344x194.jpg](https://resources.revvity.com/images/cell-and-gene-therapy-344x194.jpg)
Cell and Gene Therapy
The recent success of cell and gene therapies has paved the way for the next generation of advanced therapeutics. While challenges remain, cell and gene therapy research is seeing a transformational shift in the way that novel modalities, such as CAR-T, CRISPR, and vectors, are developed and delivered.
![disease-research_512x288.jpg](https://resources.revvity.com/images/disease-research_512x288.jpg)
Disease Research
New drug modalities and targets are enabling us to live longer and healthier lives— but their development is grounded on a deep understanding of disease onset and progression.
![Drug Development](https://resources.revvity.com/images/drug-development-thumbnail-512x288.jpg)
Drug Development
The process of drug development comprises all the activities involved in bringing a new drug to market once a lead compound has been identified.
![functionalgenomic-screeninig512x288](https://resources.revvity.com/images/functionalgenomic-screeninig512x288.jpg)
Functional Genomic Screening
Identify and characterize drug discovery targets with functional genomic screening services. Offering CRISPR knockout, CRISPR activation, CRISPR inhibition, dual screening and RNAi technologies
![Integrated Lab Automation](https://resources.revvity.com/images/integrated-lab-automation-thumbnail-512x288.jpg)
Integrated Lab Automation
From cellular screening and imaging applications to high-throughput screening and genomics-based applications, custom explorer™ G3 integrated workstations
![physiological-models](https://resources.revvity.com/images/physiological-models_%20512x288.jpg)
Physiological Model Solutions
Drug discovery endeavors require a deep understanding of biological systems and their response to potential therapeutics.
![Precision Medicine_512x288.jpg](https://resources.revvity.com/images/Precision%20Medicine_512x288.jpg)
Precision Medicine Research
Countless diseases, especially cancer, are highly heterogenous in nature which means a one-drug-fitsall approach isn’t practical for treating or fighting these diseases effectively.
![drug discovery](https://resources.revvity.com/images/drug-discovery-512x288.jpg)
Small Molecule Drug Discovery
With decades of experience in drug discovery driven by strong customer relationships, Revvity has developed an excellent product portfolio of drug discovery tools for complete solutions serving all parts of the discovery workflow.
![Design Element](/themes/custom/lsdx_theme/images/background/focused-solutions-end-design.png)
![Design Element](/themes/custom/lsdx_theme/images/background/focused-solutions-end-design-mobile.png)
All Resources
Filters
109 - 120 of 975 Results
![Other Icon](/sites/default/files/2024-06/icon-other-18.png)
Genomic breakpoint analysis facilitates identification of complex rearrangements and re-…
This poster highlights results emphasize the importance of utilizing breakpoint
![Other Icon](/sites/default/files/2024-06/icon-other-18.png)
Beyond Single Nucleotide Variants and Copy Number Variations: Spinal Muscular Atrophy and Repeat…
The utilization of short-read WGS to screen SMA and STR disorders will increase
![Other Icon](/sites/default/files/2024-06/icon-other-18.png)
Identification of Multiple Diagnoses in Pediatric Patients through Genome Sequencing
This study solely utilizes genome sequencing to assess the prevalence of MGD
![Other Icon](/sites/default/files/2024-06/icon-other-18.png)
Comparison of GLA variant profile in newborn screening confirmatory testing and diagnostic testing…
Comparison of the GLA variant profiles between the NBS cohort and the diagnostic
![Application Note Icon](/sites/default/files/2024-06/icon-application-note-18.png)
High-throughput, end-to-end Cell Free DNA (cfDNA) analysis workflow from plasma
Automating your cfDNA analysis workflow from plasma using Revvity automated
![Other Icon](/sites/default/files/2024-06/icon-other-18.png)
Recognizing the Promise and Potential Pitfalls of Genomic Medicine Through Routine Rapid Whole…
This poster explains WGS from DBS reduces the challenges associated with sample
![Application Note Icon](/sites/default/files/2024-06/icon-application-note-18.png)
Detection of the bacterial 16S rRNA gene from soil samples using the Omni Bead Ruptor Elite bead…
We demonstrate the effective extraction of microbial 16S rRNA from soil using
![Application Note Icon](/sites/default/files/2024-06/icon-application-note-18.png)
Extraction of free testosterone from equine hair on the Omni Bead Ruptor Elite bead mill homogenizer
Discover how bead milling enhances testosterone extraction from horsehair for
![Whitepaper Icon](/sites/default/files/2024-06/icon-white-paper-18.png)
High content screening in three dimensions
This paper provides a recommended workflow for 3D HCS analysis, with a focus on
![Application Note Icon](/sites/default/files/2024-06/icon-application-note-18.png)
Fast Kinetic Calcium Flux Imaging Using the Opera Phenix Plus High-Content Screening System
Application Note - Fast Kinetic Calcium Flux Imaging Using the Opera Phenix Plus
![Infographic Icon](/sites/default/files/2024-06/icon-infographic-18.png)
The impact of no-call rate in NIPT
A reference that highlights the clinical importance of no-call rate in NIPT (non
![resource-center-page-end-card-bg-illuminator.png](https://resources.revvity.com/images/resource-center-page-end-card-bg-illuminator.png?format=webp&)
![resource-center-page-end-card-bg-illuminator-mobile.png](https://resources.revvity.com/images/resource-center-page-end-card-bg-illuminator-mobile.png?format=webp&)
Looking for technical documents?
Find the technical documents you need, ASAP, in our easy-to-search library.